Kuhn W - Search Results

1

Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential.

Mueller J, Brebeck B, Schmalfeldt B, Kuhn W, Graeff H, Höfler H. Mueller J, et al. Among authors: kuhn w. Virchows Arch. 2000 Dec;437(6):618-24. doi: 10.1007/s004280000261. Virchows Arch. 2000. PMID: 11193473

2

Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer.

Sassen S, Schmalfeldt B, Avril N, Kuhn W, Busch R, Höfler H, Fend F, Nährig J. Sassen S, et al. Among authors: kuhn w. Hum Pathol. 2007 Jun;38(6):926-34. doi: 10.1016/j.humpath.2006.12.008. Epub 2007 Mar 30. Hum Pathol. 2007. PMID: 17397905

3

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Schmalfeldt B, et al. Among authors: kuhn w. Cancer Res. 1995 Sep 15;55(18):3958-63. Cancer Res. 1995. PMID: 7664262

The relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI) type 1 in predicting the survival probability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors h …

The relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI) type 1 in predicting the survival prob …

4

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Kuhn W, et al. Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9. doi: 10.1006/gyno.1994.1313. Gynecol Oncol. 1994. PMID: 7835780

5

Disease-adapted relapse therapy for ovarian cancer: results of a prospective study.

Kuhn W, Schmalfeldt B, Pache L, Späthe K, Ulm K, Renziehausen K, Nöschel H, Canzler E, Richter B, Kroner M, Tilch G, Janicke F, Graeff H. Kuhn W, et al. Int J Oncol. 1998 Jul;13(1):57-63. Int J Oncol. 1998. PMID: 9625803 Clinical Trial.

6

HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.

Harbeck N, Ross JS, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M. Harbeck N, et al. Among authors: kuhn w. Int J Oncol. 1999 Apr;14(4):663-71. doi: 10.3892/ijo.14.4.663. Int J Oncol. 1999. PMID: 10087312

7

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.

Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H. Kuhn W, et al. Br J Cancer. 1999 Apr;79(11-12):1746-51. doi: 10.1038/sj.bjc.6690278. Br J Cancer. 1999. PMID: 10206287 Free PMC article.

8

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Schmalfeldt B, et al. Among authors: kuhn w. Clin Cancer Res. 2001 Aug;7(8):2396-404. Clin Cancer Res. 2001. PMID: 11489818

9

Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.

Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Lengyel E, et al. Among authors: kuhn w. Gynecol Oncol. 2001 Aug;82(2):291-8. doi: 10.1006/gyno.2001.6243. Gynecol Oncol. 2001. PMID: 11531282

10

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.

Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H. Kuhn W, et al. Cancer. 2001 Nov 15;92(10):2585-91. doi: 10.1002/1097-0142(20011115)92:10<2585::aid-cncr1611>3.0.co;2-#. Cancer. 2001. PMID: 11745193 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

932 results

Search Page

Filters